What is Polyneuron Pharmaceuticals?
Polyneuron Pharmaceuticals is a biopharmaceutical company at the forefront of developing targeted therapies for autoimmune diseases. Leveraging its proprietary Antibody-Catch technology, the company designs biodegradable injectable glycopolymers engineered to selectively neutralize pathological autoantibodies while preserving essential immune functions. Established in 2014 as a spin-off from the University of Basel, Polyneuron is focused on addressing critical unmet medical needs in severe autoimmune conditions. The company's lead candidate, PN-1007, is currently undergoing Phase I clinical trials, marking a crucial step in its journey from research to patient care.
How much funding has Polyneuron Pharmaceuticals raised?
Polyneuron Pharmaceuticals has raised a total of $43M across 2 funding rounds:
Angel/Seed
$3.1M
Series A
$39.9M
Angel/Seed (2016): $3.1M with participation from Zorcher Kantonalbank and EVA Basel
Series A (2020): $39.9M led by Sofinnova Partners, HBM Healthcare Investments, and New Enterprise Associates
Key Investors in Polyneuron Pharmaceuticals
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. They actively partner with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations.
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded investment company with a diversified portfolio in the global healthcare sector, aiming to capitalize on growth opportunities driven by demographic trends and medical advancements.
New Enterprise Associates
New Enterprise Associates (NEA) is a venture capital firm focused on helping entrepreneurs build businesses, with a history dating back to 1977 and a strong presence in Silicon Valley.
What's next for Polyneuron Pharmaceuticals?
The recent major strategic investment signals a pivotal growth phase for Polyneuron Pharmaceuticals, likely enabling the acceleration of its clinical development pipeline, particularly for PN-1007. This backing will be instrumental in advancing the company's mission to bring its selective autoantibody elimination technology to patients suffering from debilitating autoimmune disorders. Future endeavors will likely focus on completing ongoing trials, potentially initiating further clinical studies, and scaling operations to meet the demands of bringing a novel therapeutic to market. The company's trajectory suggests a strong focus on translating its scientific innovation into tangible patient benefits.
See full Polyneuron Pharmaceuticals company page
